R. Ravasio, M. Tiseo, L. Pradelli, M. Bellone, A. Gervasi, and M. Coffani, “Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer”, Grhta, vol. 6, no. 1, Jun. 2019.